NOVARTIS INDIA LIMITED (NOVARTIND) financials

NOVARTIS INDIA LIMITED (NOVARTIND) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods.[1]It imports various medicines to India from different sources across the globe.[2]

  • Market Cap: ₹4,971Cr.
  • Current Price: ₹2,013
  • Stock P/E: 50.8
  • ROE: 11.6%
  • ROCE: 16.3%
  • Book Value: ₹331
  • Dividend Yield: 0.00%
  • 52W High / Low: ₹2,589/750

In Jun 2026, NOVARTIS INDIA LIMITED (NOVARTIND) reported sales ₹104 Cr and net profit ₹32 Cr.

Annual TTM: sales ₹371 Cr, net profit ₹98 Cr.

Shareholding: Promoters 70.68% (Jul 2026), FIIs 0.15% (Jul 2026), DIIs 1.39% (Jul 2026), Public 27.79% (Jul 2026), No. of Shareholders 36,706% (Jul 2026).

NOVARTIND quarterly results (₹ Cr.)
CategorySep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales87938488908691104
Expenses6967606066647069
Operating Profit1826242724222135
OPM %21%28%29%31%26%26%23%34%
Other Income1011111199109
Interest00000100
Depreciation11111000
Profit before tax2835343733303043
Tax %26%28%14%26%26%46%16%25%
Net Profit2025292824162532
EPS in Rs8.2710.3111.8711.199.816.5210.2313.05
Raw PDF————————
NOVARTIND profit and loss (₹ Cr.)
CategoryMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales438381400379335356354371
Expenses426355373314270265260269
Operating Profit12272765659194102
OPM %2.8%7%7%17%19%26%27%27%
Other Income3633-175862423937
Interest68521111
Depreciation13121063222
Profit before tax2940-4115123130130136
Tax %65%48%-3%10%31%23%28%—
Net Profit1021-4103851019398
EPS in Rs4.088.46-1.5141.8634.5040.8737.7439.61
Dividend Payout %245%118%-663%113%72%61%66%—
NOVARTIND balance sheet (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital1212121212121212
Reserves747708699679763732773805
Borrowings068622422753
Other Liabilities223289229242186173158157
Total Liabilities9821,0781,002958983925948978
Fixed Assets1576642419753
CWIP00000000
Investments00000000
Other Assets9671,001938934964918943975
Total Assets9821,0781,002958983925948978
NOVARTIND cash flows (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-194-23-6939451137547
Cash from Investing Activity274569587-15333-318
Cash from Financing Activity-30-41-37-36-30-121-64-64
Net Cash Flow50-9-1190-1392670
Free Cash Flow-208-24-6938451137546
CFO/OP-1,210%124%-127%210%65%115%99%87%
NOVARTIND shareholding pattern (%)
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Jul 2026
Promoters70.68%70.68%70.68%70.68%70.68%70.68%70.68%70.68%
FIIs0.19%0.19%0.19%0.19%0.19%0.17%0.16%0.15%
DIIs0.53%0.53%0.53%0.53%0.63%0.53%1.35%1.39%
Public28.60%28.61%28.60%28.61%28.50%28.60%27.81%27.79%
No. of Shareholders38,92639,13339,04039,35339,46838,11636,50236,706
NOVARTIND key ratios
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days3431374135454138
Inventory Days11111711911799827498
Days Payable16814513714810811293101
Cash Conversion Cycle-233191026152236
Working Capital Days7-162-23-37-59-45-46
ROCE %12%5%6%6%15%16%17%16%
NOVARTINDUpdated 13 Oct 2026, 7:12

Novartis India Limited

Market Cap

₹4,971Cr.

Current Price

₹2,013

High / Low

₹2,589/750

Stock P/E

50.8

ROE11.6%
ROCE16.3%
Book Value₹331
Face Value₹5.00
Dividend Yield0.00%

About

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods.[1]It imports various medicines to India from different sources across the globe.[2]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Jul 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios
CategoryMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days352723283431374135454138
Inventory Days103921048411111711911799827498
Days Payable98898715816814513714810811293101
Cash Conversion Cycle403040-45-233191026152236
Working Capital Days6-35-14-997-162-23-37-59-45-46
ROCE %9%22%9%17%12%5%6%6%15%16%17%16%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of NOVARTIS INDIA LIMITED (NOVARTIND)?

The reported market capitalisation for NOVARTIS INDIA LIMITED (NOVARTIND) is ₹4,971Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of NOVARTIND?

The current price shown for NOVARTIS INDIA LIMITED (NOVARTIND) on Fincrux is ₹2,013 with a 52-week high/low of ₹2,589/750.

What is the P/E ratio of NOVARTIS INDIA LIMITED (NOVARTIND)?

The stock P/E for NOVARTIS INDIA LIMITED (NOVARTIND) is 50.8 on Fincrux, with ROE at 11.6% and ROCE at 16.3%.

What were NOVARTIND latest quarterly results?

For Jun 2026, NOVARTIS INDIA LIMITED (NOVARTIND) reported sales ₹104 Cr and net profit ₹32 Cr (figures in ₹ crore unless noted).

What are NOVARTIND annual sales and net profit?

For TTM, NOVARTIS INDIA LIMITED (NOVARTIND) shows sales of ₹371 Cr and net profit of ₹98 Cr on the Fincrux profit & loss statement.

Who owns NOVARTIS INDIA LIMITED (NOVARTIND)?

Latest shareholding for NOVARTIS INDIA LIMITED (NOVARTIND) on Fincrux: Promoters 70.68% (Jul 2026), FIIs 0.15% (Jul 2026), DIIs 1.39% (Jul 2026), Public 27.79% (Jul 2026), No. of Shareholders 36,706% (Jul 2026).

Where can I find NOVARTIS INDIA LIMITED (NOVARTIND) financials?

NOVARTIS INDIA LIMITED (NOVARTIND) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show NOVARTIND balance sheet and cash flow?

Yes. The NOVARTIS INDIA LIMITED (NOVARTIND) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 7:12


Designed & Shipped by Harshit Bansal